Literature DB >> 23744037

An MLL-dependent network sustains hematopoiesis.

Erika L Artinger1, Bibhu P Mishra, Kristin M Zaffuto, Bin E Li, Elaine K Y Chung, Adrian W Moore, Yufei Chen, Chao Cheng, Patricia Ernst.   

Abstract

The histone methyltransferase Mixed Lineage Leukemia (MLL) is essential to maintain hematopoietic stem cells and is a leukemia protooncogene. Although clustered homeobox genes are well-characterized targets of MLL and MLL fusion oncoproteins, the range of Mll-regulated genes in normal hematopoietic cells remains unknown. Here, we identify and characterize part of the Mll-dependent transcriptional network in hematopoietic stem cells with an integrated approach by using conditional loss-of-function models, genomewide expression analyses, chromatin immunoprecipitation, and functional rescue assays. The Mll-dependent transcriptional network extends well beyond the previously appreciated Hox targets, is comprised of many characterized regulators of self-renewal, and contains target genes that are both dependent and independent of the MLL cofactor, Menin. Interestingly, PR-domain containing 16 emerged as a target gene that is uniquely effective at partially rescuing Mll-deficient hematopoietic stem and progenitor cells. This work highlights the tissue-specific nature of regulatory networks under the control of MLL/Trithorax family members and provides insight into the distinctions between the participation of MLL in normal hematopoiesis and in leukemia.

Entities:  

Keywords:  HSC; epigenetics; proliferation

Mesh:

Substances:

Year:  2013        PMID: 23744037      PMCID: PMC3718146          DOI: 10.1073/pnas.1301278110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

Review 1.  Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis.

Authors:  Angelika Daser; Terence H Rabbitts
Journal:  Genes Dev       Date:  2004-05-01       Impact factor: 11.361

2.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

Review 3.  Polycomb silencers control cell fate, development and cancer.

Authors:  Anke Sparmann; Maarten van Lohuizen
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

4.  MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.

Authors:  Qian-Fei Wang; George Wu; Shuangli Mi; Fuhong He; Jun Wu; Jingfang Dong; Roger T Luo; Ryan Mattison; Joseph J Kaberlein; Shyam Prabhakar; Hongkai Ji; Michael J Thirman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

5.  Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways.

Authors:  Akihiko Yokoyama; Francesca Ficara; Mark J Murphy; Christian Meisel; Alpana Naresh; Issay Kitabayashi; Michael L Cleary
Journal:  J Cell Sci       Date:  2011-07-01       Impact factor: 5.285

6.  Prdm16 is a physiologic regulator of hematopoietic stem cells.

Authors:  Francesca Aguilo; Serine Avagyan; Amy Labar; Ana Sevilla; Dung-Fang Lee; Parameet Kumar; Ihor R Lemischka; Betty Y Zhou; Hans-Willem Snoeck
Journal:  Blood       Date:  2011-02-22       Impact factor: 22.113

7.  MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.

Authors:  R Sood; A Talwar-Trikha; S R Chakrabarti; G Nucifora
Journal:  Leukemia       Date:  1999-03       Impact factor: 11.528

8.  The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.

Authors:  Akihiko Yokoyama; Tim C P Somervaille; Kevin S Smith; Orit Rozenblatt-Rosen; Matthew Meyerson; Michael L Cleary
Journal:  Cell       Date:  2005-10-21       Impact factor: 41.582

9.  Gene expression profiling of pediatric acute myelogenous leukemia.

Authors:  Mary E Ross; Rami Mahfouz; Mihaela Onciu; Hsi-Che Liu; Xiaodong Zhou; Guangchun Song; Sheila A Shurtleff; Stanley Pounds; Cheng Cheng; Jing Ma; Raul C Ribeiro; Jeffrey E Rubnitz; Kevin Girtman; W Kent Williams; Susana C Raimondi; Der-Cherng Liang; Lee-Yung Shih; Ching-Hon Pui; James R Downing
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

Review 10.  Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

Authors:  Aniruddha J Deshpande; James Bradner; Scott A Armstrong
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

View more
  41 in total

1.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

2.  Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.

Authors:  Fang Cao; Elizabeth C Townsend; Hacer Karatas; Jing Xu; Li Li; Shirley Lee; Liu Liu; Yong Chen; Peter Ouillette; Jidong Zhu; Jay L Hess; Peter Atadja; Ming Lei; Zhaohui S Qin; Sami Malek; Shaomeng Wang; Yali Dou
Journal:  Mol Cell       Date:  2014-01-02       Impact factor: 17.970

3.  Delineating the mixed lineage leukemia gene expression network in hematopoietic stem cells.

Authors:  Sidinh Luc; Stuart H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-03       Impact factor: 11.205

Review 4.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

5.  The subtype-specific features of EVI1 and PRDM16 in acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Susumu Goyama; Yasuhiko Kamikubo; Souichi Adachi
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

6.  Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Authors:  Dmitry Borkin; Shihan He; Hongzhi Miao; Katarzyna Kempinska; Jonathan Pollock; Jennifer Chase; Trupta Purohit; Bhavna Malik; Ting Zhao; Jingya Wang; Bo Wen; Hongliang Zong; Morgan Jones; Gwenn Danet-Desnoyers; Monica L Guzman; Moshe Talpaz; Dale L Bixby; Duxin Sun; Jay L Hess; Andrew G Muntean; Ivan Maillard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Cancer Cell       Date:  2015-03-26       Impact factor: 31.743

7.  Transcription factor Hoxb5 reprograms B cells into functional T lymphocytes.

Authors:  Mengyun Zhang; Yong Dong; Fangxiao Hu; Dan Yang; Qianhao Zhao; Cui Lv; Ying Wang; Chengxiang Xia; Qitong Weng; Xiaofei Liu; Chen Li; Peiqing Zhou; Tongjie Wang; Yuxian Guan; Rongqun Guo; Lijuan Liu; Yang Geng; Hongling Wu; Juan Du; Zheng Hu; Sheng Xu; Jiekai Chen; Aibin He; Bing Liu; Demin Wang; Yong-Guang Yang; Jinyong Wang
Journal:  Nat Immunol       Date:  2018-02-12       Impact factor: 25.606

8.  MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.

Authors:  Simone S Riedel; Jessica N Haladyna; Matthew Bezzant; Brett Stevens; Daniel A Pollyea; Amit U Sinha; Scott A Armstrong; Qi Wei; Roy M Pollock; Scott R Daigle; Craig T Jordan; Patricia Ernst; Tobias Neff; Kathrin M Bernt
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

9.  Deconvoluting MLL1-dependent pathways in hematopoiesis and leukemogenesis.

Authors:  B P Mishra; P Ernst
Journal:  Leuk Suppl       Date:  2014-12-17

10.  Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.

Authors:  Nilda L Alicea-Velázquez; Stephen A Shinsky; Daniel M Loh; Jeong-Heon Lee; David G Skalnik; Michael S Cosgrove
Journal:  J Biol Chem       Date:  2016-08-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.